Skip to main content

Table 3 Meta-analyses estimating the combined effect and 95% confidence interval of the minor allele ofPTBP1rs11085226 in the Family- and Youth92 study (n= 596) assuming an additive and dominant model of inheritance

From: Impact of PTBP1 rs11085226 on glucose-stimulated insulin release in adult Danes

 

Additive inheritance

Dominant inheritance

 

Fixed effect model

Random effect model

Fixed effect model

Random effect model

 

Combined effect

P

Combined effect

P

Combined effect

P

Combined effect

P

β-cell responsiveness to glucose (pmol · kg−1 · min−1/mmol · l)

0.054 (−0.097; 0.21)

0.5

0.038 (−0.23; 0.30)

0.8

−0.11 (−0.20; −0.025)

0.01

−0.13 (−0.25; 0.003)

0.06

Fasting ISR (pmol · kg−1 · min−1)

0.037 (−0.057; 0.13)

0.4

0.037 (−0.057; 0.13)

0.4

0.65 (−2.62; 3.92)

0.7

0.56 (−4.57; 5.69)

0.8

Disposition index*

−0.11 (−0.302; 0.081)

0.25

0.51 (−0.99; 2.014)

0.5

−0.1030 (−0.299; 0.093)

0.3

0.51(−0.982; 2.011)

0.96

AUC ISR0–8 min * (pmol · kg−1)

−0.0015 (−0.082; 0.079)

0.97

−0.0015 (−0.082; 0.079)

0.97

−0.060 (−0.16; 0.043)

0.3

−0.081 (−0.27; 0.11)

0.4

IncAUC ISR0–8 min (pmol · kg−1)

0.003 (−0.097; 0.10)

0.95

0.003 (−0.097; 0.10)

0.95

0.010 (−0.051; 0.072)

0.7

0.010 (−0.051; 0.072)

0.7

AUC insulin0–8 min * (pmol/l · min)

−0.043 (−0.15; 0.068)

0.4

−0.043 (−0.15; 0.068)

0.4

−0.094 (−0.29; 0.11)

0.4

−0.094 (−0.29; 0.11)

0.4

Acute phase insulin response (pmol/l · min)

−85.40 (−381.20; 210.41)

0.6

−74.47 (−407.35; 258.41)

0.7

16.73 (−215.63; 249.09)

0.9

3.30 (−288.95; 295.55)

0.98

AUC glucose0–8 min (mmol/l · min)

0.39 (−1.42; 2.20)

0.7

0.11 (−2.69; 2.91)

0.9

19.82 (−202.28; 241.92)

0.9

−5.020 (−338.55; 328.51)

0.98

IncAUC glucose0–8 min (mmol/l · min)

0.36 (−1.2163; 1.9341)

0.66

0.35 (−1.27; 1.96)

0.7

0.02 (−1.42; 1.46)

0.98

0.16(−2.22; 2.55)

0.9

AUC C-peptide0–8 min* (pmol/l · min)

−0.0019 (−0.063; 0.059)

0.95

−0.0019 (−0.0632; 0.0594)

0.95

−0.0268 (−0.124; 0.0701)

0.6

−0.0336(−0.1582; 0.0910)

0.6

Acute phase C-peptide response (pmol/l · min)

7.69 (−582.011; 597.39)

0.98

10.081 (−586.71; 606.87)

0.97

176.92 (−357.81; 711.66)

0.5

176.92 (−357.81; 711.66)

0.5

  1. Data is mean combined effect (95% CI) adjusted for age, sex, BMI, and insulin sensitivity (disposition index adjusted for age, sex, and BMI only). Estimates of traits displaying non-normality (*) were based on log transformed values. Fixed effect model represent the combined effects of the studies weight using inverse variance. The Random effects model represent the combined effects of the studies weighted using the DerSimonian-Laird method.